会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 8. 发明申请
    • MEANS AND METHODS FOR THE TREATMENT OF CATARACT AND PRESBYOPIA
    • 用于治疗感染和预后的手段和方法
    • WO2009044294A2
    • 2009-04-09
    • PCT/IB2008003602
    • 2008-06-12
    • UNIV GENEVEHOPITAUX UNIVERSITAIRES DE GENKRAUSE KARL-HEINZSERRANDER LENA
    • KRAUSE KARL-HEINZSERRANDER LENA
    • C12N9/02A61K31/713A61P27/10A61P27/12C12N15/11C12Q1/26
    • C12N9/0036A61K38/005
    • The present invention relates to an inhibitor of a protein, wherein said protein (i) comprises or consists of the amino acid sequence of SEQ ID NOs: 2 or 4, or is encoded by a nucleic acid comprising or consisting of the sequence of SEQ ID NOs: 1 or 3; (ii) comprises or consists of the amino acid sequence of SEQ ID NO: 26, or is encoded by a nucleic acid comprising or consisting of the sequence of SEQ ID NO: 25; (iii) is a fragment of the protein according to (i), or has a sequence at least 75% identical with the protein according to (i) or with said fragment of the protein according to (i), and exhibits NADPH oxidase activity; or (iv) is a fragment of the protein according to (ii) or has a sequence at least 75% identical with the protein according to (ii) or with said fragment of the protein according to (ii) and stabilizes said protein exhibiting NADPH oxidase activity; and/or an inhibitor of a nucleic acid, wherein said nucleic (v) comprises or consists of the nucleic acid sequence of SEQ ID NO: 1 or 3, or encodes a protein comprising or consisting of the sequence of SEQ ID NO: 2 or 4; (vi) comprises or consists of the nucleic acid sequence of SEQ ID NO: 25, or encodes a protein comprising or consisting of the sequence of SEQ ID NO: 26; (vii) is a fragment of the nucleic acid according to (v), or has a sequence at least 75% identical with the nucleic acid according to (v) or with said fragment of the nucleic acid according to (v), and encodes a protein exhibiting NADPH oxidase activity; or (viii) is a fragment of the nucleic acid according to (vi), or has a sequence at least 75% identical with the nucleic acid according to (vi) or with said fragment of the nucleic acid according to (vi), and encodes a protein stabilizing said protein exhibiting NADPH oxidase activity; for treatment and/or prevention of cataract and/or presbyopia. The sequences define NADPH oxidases or a subunit of an NADPH oxidase, respectively. A preferred inhibitor is a siRNA. Also provided are a method of treating cataract and presbyopia, pharmaceutical compositions, medical uses and diagnostic uses of compounds of the invention.
    • 本发明涉及蛋白质的抑制剂,其中所述蛋白质(i)包含SEQ ID NO:2或4的氨基酸序列或由SEQ ID NO:2或4的氨基酸序列组成,或由包含SEQ ID NO: NO:1或3; (ii)包含SEQ ID NO:26的氨基酸序列或由SEQ ID NO:26的氨基酸序列组成,或由包含或由SEQ ID NO:25的序列组成的核酸编码; (iii)是根据(i)的蛋白质的片段,或具有与根据(i)的蛋白质或根据(i)的蛋白质的所述片段至少75%相同的序列,并且表现出NADPH氧化酶活性 ; 或(iv)是根据(ii)的蛋白质的片段或具有与根据(ii)的蛋白质或根据(ii)的蛋白质的所述片段至少75%相同的序列,并稳定所述表达NADPH的蛋白质 氧化酶活性; 和/或核酸的抑制剂,其中所述核酸(v)包含SEQ ID NO:1或3的核酸序列或由SEQ ID NO:1或3的核酸序列组成,或编码包含SEQ ID NO:2或SEQ ID NO:2的序列或由SEQ ID NO: 4; (vi)包含SEQ ID NO:25的核酸序列或由SEQ ID NO:25的核酸序列组成,或编码包含SEQ ID NO:26的序列或由SEQ ID NO:26的序列组成的蛋白质。 (vii)是根据(v)的核酸的片段,或具有与根据(v)的核酸或根据(v)的核酸的所述片段至少75%相同的序列,并编码 表现出NADPH氧化酶活性的蛋白质; 或(viii)是根据(vi)的核酸的片段,或具有与根据(vi)的核酸或根据(vi)的核酸的所述片段至少75%相同的序列,和 编码稳定表达NADPH氧化酶活性的所述蛋白质的蛋白质; 用于治疗和/或预防白内障和/或老花眼。 序列分别定义NADPH氧化酶或NADPH氧化酶的亚基。 优选的抑制剂是siRNA。 还提供了治疗本发明化合物的白内障和老花眼的方法,药物组合物,医学用途和诊断用途。